Chris Mirabelli
Chairman chez LEAP THERAPEUTICS, INC.
Fortune : 13 529 $ au 31/03/2024
Profil
Chris K.
Mirabelli is the founder of Ionis Pharmaceuticals, Inc. (founded in 1989) and held the title of Senior Vice President-Research from 1989 to 1993.
He is currently the Chairman of Leap Therapeutics, Inc. (since 2011), Executive Chairman of Flamingo Therapeutics BV, Director of Theraclone Sciences, Inc., Director of Galleon Pharmaceuticals, Inc., Managing Director of Healthcare Partners VIII LLC, Managing Director of Healthcare Ventures LLC (since 2000), Director of Visionary Therapeutics Corp., Managing Director of Healthcare Partners IX LLC, and Managing Director of Healthcare Strategic Partners, LLC.
He is also an Independent Director of Aro Biotherapeutics Co. (since 2020), Director of Fredonia College Foundation, Trustee of Guilford College, and Member-Supervisory Board of Dynacure SA (since 2017).
In his former positions, Dr. Mirabelli served as Chairman, President & Chief Executive Officer of LeukoSite, Inc. (from 1993 to 1999), Chief Executive Officer & Director of Anexon, Inc. (from 2012 to 2014), Chairman of Thios Pharmaceuticals, Inc., Chairman of Proteostasis Therapeutics, Inc. (from 2010 to 2016), Director, President-Pharmaceutical R&D of Millennium Pharmaceuticals, Inc. (from 1999 to 2000), Director of Critical Therapeutics, Inc. (from 2001 to 2008), Director of FoldRx Pharmaceuticals LLC, President & Director of DecImmune Therapeutics, Inc., Director of Anchor Therapeutics, Inc., Director of Antisoma, Inc., Independent Director of Trevena, Inc. (from 2008 to 2014), and President of Adheron Therapeutics, Inc. He also held a position as Principal at SmithKline & French SpA.
Dr. Mirabelli obtained his undergraduate degree from The State University of New York College at Fredonia in 1977 and his doctorate degree from Baylor College of Medicine in 1981.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
LEAP THERAPEUTICS, INC.
0,02% | 29/01/2024 | 5 086 ( 0,02% ) | 13 529 $ | 31/03/2024 |
Postes actifs de Chris Mirabelli
Sociétés | Poste | Début |
---|---|---|
LEAP THERAPEUTICS, INC. | Chairman | 01/01/2016 |
HealthCare Ventures LLC
HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Private Equity Investor | 01/01/2000 |
Fredonia College Foundation
Fredonia College Foundation Miscellaneous Commercial ServicesCommercial Services The Fredonia College Foundation is a non-profit organization that supports the State University of New York at Fredonia by providing financial assistance to students, faculty, and staff. The foundation is based in Fredonia, NY. The foundation offers scholarships, grants, and other forms of aid to help students achieve their academic goals. It also supports research and other initiatives that enhance the educational experience at the university. | Director/Board Member | - |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Director/Board Member | 01/01/2017 |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Director/Board Member | 13/10/2020 |
Healthcare Strategic Partners, LLC
Healthcare Strategic Partners, LLC Medical/Nursing ServicesHealth Services Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services. | Corporate Officer/Principal | - |
Healthcare Partners IX LLC | Corporate Officer/Principal | - |
Guilford College | Director/Board Member | - |
Healthcare Partners VIII LLC | Corporate Officer/Principal | - |
░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | - |
Anciens postes connus de Chris Mirabelli
Sociétés | Poste | Fin |
---|---|---|
░░░░░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Chris Mirabelli
The State University of New York College at Fredonia | Undergraduate Degree |
Baylor College of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 2 |
---|---|
IONIS PHARMACEUTICALS, INC. | Health Technology |
TREVENA, INC. | Health Technology |
Entreprise privées | 24 |
---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
LeukoSite, Inc.
LeukoSite, Inc. Pharmaceuticals: MajorHealth Technology LeukoSite, Inc. develops drugs for treatment of cancer and inflammatory diseases. It produces drugs to block autoimmune and viral diseases associated with malfunctioning leukocytes or white blood cells. The company was founded in 1992 and is located in Cambridge, MA. | Health Technology |
Critical Therapeutics, Inc. | Health Technology |
FoldRx Pharmaceuticals LLC
FoldRx Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology FoldRx Pharmaceuticals, Inc. provides drug discovery and clinical development services. It develops and discovers products focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding. The company was founded by Jeffery W. Kelly and Susan L. Lindquist in 2003 and is headquartered in Cambridge, MA. | Health Technology |
Thios Pharmaceuticals, Inc.
Thios Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Thios Pharmaceuticals, Inc. was engaged in providing researches therapies. The therapies provided by the company target sulfation pathways, which could lead to potential for treatments for inflammation, cancer and other diseases. Thios Pharmaceuticals was located in Oakland, CA. | Health Technology |
Theraclone Sciences, Inc.
Theraclone Sciences, Inc. Miscellaneous Commercial ServicesCommercial Services Theraclone Sciences, Inc. develops novel therapeutic antibodies for the treatment of cancer and infectious diseases. The firm leverages its proprietary antibody discovery technology, I-STARTM to identify rare fully human antibodies from immunologically relevant human subjects. The firm’s primary research focus is to discover novel targets and antibodies, and develop therapeutic monoclonal antibodies, by using its proprietary B-cell technology platform to mine the immune system of cancer patients. The company was founded by Johnny T. Stine in November 2004 and is headquartered in Seattle, WA. | Commercial Services |
Adheron Therapeutics, Inc.
Adheron Therapeutics, Inc. BiotechnologyHealth Technology Adheron Therapeutics, Inc. discovers and develops therapeutic drugs. The firm offers Cadherin-11 antagonists for the treatment of rheumatoid arthritis and fibrotic diseases including pulmonary fibrosis and skin fibrosis. The company was founded by David Lee, Michael B. Brenner, and David L. Castaldi in 2006 and is headquartered in Berkeley, CA. | Health Technology |
DecImmune Therapeutics, Inc.
DecImmune Therapeutics, Inc. BiotechnologyHealth Technology DecImmune Therapeutics, Inc. develops novel peptides and antibodies for acute and tissue damaging inflammation. It engages in developing an antibody-based therapeutic that can prevent tissue damage and preserve organ function by inhibiting activation of the N2 neoepitope in the innate autoimmune pathway. The company was founded by Michael Carroll, Richard S. Foemmel, and Francis Moore Jr. on March 27, 2001 and is headquartered in Cambridge, MA.^ | Health Technology |
Galleon Pharmaceuticals, Inc.
Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Health Technology |
Anchor Therapeutics, Inc.
Anchor Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Anchor Therapeutics, Inc. designs and develops peptide modulators of G protein-coupled receptors (GPCRs). The firm engages in developing and licensing pepducin technology as a research tool for drug development; and pepducin drug candidates and novel molecules that are intended for targeting GPCR to allosterically modulate GPCR signaling. Its pepducin lipopeptides are designed to allosterically modulate internal cell signaling via specific interactions with intracellular GPCR domains. The company also focuses on developing its pepducin technology for creating new treatment options for regenerative medicine, diabetes, inflammation, and cancer. Anchor Therapeutics was founded by Thomas J. McMurry and Athan Kuliopulos in 2006 and is headquartered in Cambridge, MA. | Health Technology |
Healthcare Partners VIII LLC | |
HealthCare Ventures LLC
HealthCare Ventures LLC Investment ManagersFinance HealthCare Ventures LLC (HealthCare Ventures) is a venture capital firm founded in 1985 by Harold R. Werner. The firm is headquartered in Cambridge, Massachusetts. | Finance |
SmithKline & French SpA
SmithKline & French SpA Pharmaceuticals: MajorHealth Technology Part of Procter & Gamble Co., SmithKline & French SpA is a pharmaceutical concern. SmithKline & French was acquired by Procter & Gamble Co. from Smithkline Beecham Plc on September 29, 1993. | Health Technology |
Antisoma, Inc.
Antisoma, Inc. Pharmaceuticals: MajorHealth Technology Antisoma, Inc. develops drugs and pharmaceuticals. The firm's products include Xanafide, Symadex, and Clomet. Its products are used in clinical and preclinical development for multiple cancer indications. The company was founded in 2001 and is headquartered Cambridge, MA. | Health Technology |
Visionary Therapeutics Corp.
Visionary Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Visionary Therapeutics Corp. develops ocular therapeutics for eye diseases. The company was founded by Steve Hutcherson and is headquartered in Richmond, VA | Health Technology |
Anexon, Inc.
Anexon, Inc. Pharmaceuticals: MajorHealth Technology Anexon, Inc. develops therapeutics for cardiovascular diseases. The firm develops an alternatively spliced variant of brain natriuretic peptide, ANX-042, for the treatment of patients with chronic heart failure and kidney dysfunction. The company was founded in 2006 by Robert D. Simari and is headquartered in Cambridge, MA. | Health Technology |
Proteostasis Therapeutics, Inc.
Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Leap Therapeutics, Inc. | |
Dynacure SA
Dynacure SA Medical/Nursing ServicesHealth Services Dynacure SA is a clinical-stage company, which engages in developing and commercializing novel therapies to transform the lives of patients with rare diseases who have limited or no treatment options. Its product includes, DYN101, an antisense oligonucleotide, or ASO, designed to be a disease-modifying medicine for treatment of the majority of ntronuclear myopathies patients with multiple mutations in adult and pediatric populations. The company was founded by Belinda Cowling in 2016 and is headquartered in Illikirch-Graffenstaden, France. | Health Services |
Healthcare Strategic Partners, LLC
Healthcare Strategic Partners, LLC Medical/Nursing ServicesHealth Services Part of HealthCare Ventures LLC, Healthcare Strategic Partners, LLC is an American company that provides healthcare services. | Health Services |
Aro Biotherapeutics Co.
Aro Biotherapeutics Co. BiotechnologyHealth Technology Aro Biotherapeutics Co. operates as a biotechnology company which focuses on the research and development of a new generation of protein biologics products. It specializes in oncology, drug discovery, drug development, licensing, drug delivery, sirna, immunology, bispecifics, protein conjugation, protein therapeutics and protein engineering services. The company was founded by Karyn O?Neil and Susan Dillon in 2018 and is headquartered in Philadelphia, PA. | Health Technology |
Flamingo Therapeutics BV
Flamingo Therapeutics BV Miscellaneous Commercial ServicesCommercial Services Flamingo Therapeutics BV is a Belgian company that specializes in developing RNA-targeted therapies for oncology. The company is based in Leuven, Belgium and was founded by Mike Garrett and Floor Stam. Flamingo is dedicated to delivering therapeutic benefit to patients living with cancer and believes that their programs and approach can successfully address large unmet medical needs where RNA-targeting can be effective. The company's clinical-stage pipeline focuses on targeting undruggable transcription factors and splice variants. The CEO is Stephane van Rooijen. | Commercial Services |
Fredonia College Foundation
Fredonia College Foundation Miscellaneous Commercial ServicesCommercial Services The Fredonia College Foundation is a non-profit organization that supports the State University of New York at Fredonia by providing financial assistance to students, faculty, and staff. The foundation is based in Fredonia, NY. The foundation offers scholarships, grants, and other forms of aid to help students achieve their academic goals. It also supports research and other initiatives that enhance the educational experience at the university. | Commercial Services |
Healthcare Partners IX LLC |